ReviewClinical & developmental immunology2012
Rituximab-based treatment, HCV replication, and hepatic flares.
Review in Clinical & developmental immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 49 citations in OpenAlex.
- Pharmacological considerations in pharmacotherapy of rheumatology patients with liver disease: a brief narrative review.Reumatologia · 2024Review
- HCV Reactivation in a Patient with Hepatocellular Carcinoma Due to Sorafenib: A Case Report.International medical case reports journal · 2024Article
- Hepatitis C Virus (HCV)-Ribonucleic Acid (RNA) As a Biomarker for Lymphoid Malignancy with HCV Infection.Cancers · 2023Review
- Review
- Off-Label Uses of Rituximab in Dermatology.Current dermatology reports · 2022Review
- Occult Infection with Hepatitis C Virus: Looking for Clear-Cut Boundaries and Methodological Consensus.Journal of clinical medicine · 2021Review
- Immune Thrombocytopenic Purpura Complicated by Hepatitis C Virus-related Membranoproliferative Glomerulonephritis after Rituximab Therapy.Internal medicine (Tokyo, Japan) · 2021Article
- Autoimmune Pemphigus: Latest Advances and Emerging Therapies.Frontiers in molecular biosciences · 2021Review
- Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.Clinical microbiology reviews · 2020Review
- Reactivation of hepatitis B virus infection in patients with hemo-lymphoproliferative diseases, and its prevention.World journal of gastroenterology · 2019Review
- B cell therapy in ANCA-associated vasculitis: current and emerging treatment options.Nature reviews. Rheumatology · 2018Review
- Atypical Endobronchial Carcinoid with Postobstructive Pneumonia Obscuring the Diagnosis of Granulomatosis with Polyangiitis.Case reports in rheumatology · 2015Article
- Hepatic flares in chronic hepatitis C: spontaneous exacerbation vs hepatotropic viruses superinfection.World journal of gastroenterology · 2014Review
- Targeting insulin-like growth factor 1 leads to amelioration of inflammatory demyelinating disease.PloS one · 2014Article
- Rituximab for the treatment of rheumatoid arthritis: an update.Drug design, development and therapy · 2013Review
- Clinical use of biologics in vasculitis syndromes.Biologics : targets & therapy · 2012Article
- Article
- Hepatitis C Virus in the Hematology/Oncology Patient.Journal of the advanced practitioner in oncologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rituximab, a chimeric mouse-human monoclonal antibody directed to the CD20 antigen expressed on pre-B lymphocytes and mature lymphocytes, causes a profound B-cell depletion. Due to its peculiar characteristics, this drug has been used to treat oncohaematological diseases, B cell-related autoimmune diseases, rheumatoid arthritis, and, more recently, HCV-associated mixed cryoglobulinaemic vasculitis. Rituximab-based treatment, however, may induce an increased replication of several viruses such as hepatitis B virus, cytomegalovirus, varicella-zoster virus, echovirus, and parvovirus B19. Recent data suggest that rituximab-based chemotherapy induces an increase in HCV expression in hepatic cells, which may become a target for a cell-mediated immune reaction after the withdrawal of treatment and the restoration of the immune control. Only a few small studies have investigated the occurrence of HCV reactivation and an associated hepatic flare in patients with oncohaematological diseases receiving R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). These studies suggest that the hepatic flares are frequently asymptomatic, but life-threatening liver failure occurs in nearly 10% of cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.